Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

clinical trial

Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT03838263

P6099clinical trial phasephase II clinical trialQ42824440
P17countryFranceQ142
P582end time2020-12-01
P921main subjectnivolumabQ7041828
P2899minimum age18
P1132number of participants61
P4844research interventioncisplatinQ412415
P6153research siteInstitut Gustave RoussyQ266227
Curie InstituteQ2451973
Beaujon HospitalQ2690409
hôpital FochQ3145155
Tenon HospitalQ3145241
???Q2944818
P1813short nameIMMUNEBOOST
P580start time2019-03-01
P8363study typeinterventional studyQ78089383
P1476titleA Multicenter, Randomized, Open Label, Phase II Study Evaluating the Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

Search more.